Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
pharma · Phenylketonuria · Amyotrophic Lateral Sclerosis · PTCT
PTC THERAPEUTICS
PTC THERAPEUTICS, INC.
PTC THERAPEUTICS drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
500 Warren Corporate Center Drive, Warren, NJ 07059, US HQ
1998 Founded
1,153 Employees
Public company Type
PTCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 Warren Corporate Center Drive, Warren, NJ 07059, US
- Founded
- 1998
- Employees
- 1,153
- Programs
- 52
- Drugs
- 21
- Patents
- 149
PTC THERAPEUTICS pipeline
Portfolio lens on 21 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PTC THERAPEUTICS drug portfolio — 21 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
ataluren
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in PTC THERAPEUTICS's portfolio. Molecular target: 80S Ribosome.
- Target
- 80S Ribosome
- Mechanism
- 80S Ribosome modulator
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor agonist
-
eladocagene exuparvovec
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in PTC THERAPEUTICS's portfolio. Molecular target: DDC.
- Target
- DDC
- Mechanism
- DDC exogenous gene
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.
- Target
- Bacterial DNA-directed RNA polymerase
- Mechanism
- Bacterial DNA-directed RNA polymerase inhibitor
-
sapropterin
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in PTC THERAPEUTICS's portfolio. Mechanism: Phenylalanine-4-hydroxylase activator.
- Mechanism
- Phenylalanine-4-hydroxylase activator
-
US regulatory status: approved. Molecular target: Phenylalanine-4-hydroxylase.
- Target
- Phenylalanine-4-hydroxylase
- Mechanism
- Phenylalanine-4-hydroxylase activator
-
sepiapterin
Alimentary tract and metabolism (A16)US regulatory status: approved.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to PTC THERAPEUTICS in public FDA and regional records.